296 related articles for article (PubMed ID: 36041258)
1. Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours.
Wang Q; Zhang J
Eur J Med Chem; 2022 Nov; 242():114690. PubMed ID: 36041258
[TBL] [Abstract][Full Text] [Related]
2. A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Li Y; Liu CF; Rao GW
Curr Med Chem; 2021; 28(8):1565-1584. PubMed ID: 32164505
[TBL] [Abstract][Full Text] [Related]
3. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
4. Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Boussios S; Abson C; Moschetta M; Rassy E; Karathanasi A; Bhat T; Ghumman F; Sheriff M; Pavlidis N
Drugs R D; 2020 Jun; 20(2):55-73. PubMed ID: 32215876
[TBL] [Abstract][Full Text] [Related]
5. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
[TBL] [Abstract][Full Text] [Related]
6. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
7. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Bruin MAC; Sonke GS; Beijnen JH; Huitema ADR
Clin Pharmacokinet; 2022 Dec; 61(12):1649-1675. PubMed ID: 36219340
[TBL] [Abstract][Full Text] [Related]
9. PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.
Zeng Y; Arisa O; Peer CJ; Fojo A; Figg WD
Semin Oncol; 2024; 51(1-2):19-24. PubMed ID: 37880048
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
11. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
12. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
Chen Y; Du H
Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102
[TBL] [Abstract][Full Text] [Related]
13. 'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors.
Rao PD; Sankrityayan H; Srivastava A; Kulkarni YA; Mulay SR; Gaikwad AB
Drug Discov Today; 2020 Jul; 25(7):1253-1261. PubMed ID: 32371137
[TBL] [Abstract][Full Text] [Related]
14. Advances in Development of Selective Antitumor Inhibitors That Target PARP-1.
Liu F; Chen J; Li X; Liu R; Zhang Y; Gao C; Shi D
J Med Chem; 2023 Dec; 66(24):16464-16483. PubMed ID: 38088333
[TBL] [Abstract][Full Text] [Related]
15. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
16. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Kumar C; Rani N; Velan Lakshmi PT; Arunachalam A
Future Med Chem; 2017 Jan; 9(1):37-60. PubMed ID: 27995810
[TBL] [Abstract][Full Text] [Related]
18. A review on mechanisms of resistance to PARP inhibitors.
Desai C; Pathak A; Limaye S; Maniar V; Joshi A
Indian J Cancer; 2022 Mar; 59(Supplement):S119-S129. PubMed ID: 35343196
[TBL] [Abstract][Full Text] [Related]
19. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
[TBL] [Abstract][Full Text] [Related]
20. Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Gunderson CC; Moore KN
Future Oncol; 2015; 11(5):747-57. PubMed ID: 25757679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
